Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Transient MEK inhibitor-associated retinopathy in metastatic melanoma
U. Urner‐Bloch, Martin Urner, P. Stieger, et al.
Annals of Oncology (2014) Vol. 25, Iss. 7, pp. 1437-1441
Open Access | Times Cited: 126

Showing 1-25 of 126 citing articles:

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin, Paolo A. Ascierto, Brigitte Dréno, et al.
New England Journal of Medicine (2014) Vol. 371, Iss. 20, pp. 1867-1876
Open Access | Times Cited: 1904
Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis
Alejandra Daruich, Alexandre Matet, Ali Dirani, et al.
Progress in Retinal and Eye Research (2015) Vol. 48, pp. 82-118
Open Access | Times Cited: 837
Mechanisms of macular edema: Beyond the surface
Alejandra Daruich, Alexandre Matet, Alexandre Moulin, et al.
Progress in Retinal and Eye Research (2017) Vol. 63, pp. 20-68
Open Access | Times Cited: 560
Central serous chorioretinopathy: Towards an evidence-based treatment guideline
Thomas J. van Rijssen, Elon H. C. van Dijk, Suzanne Yzer, et al.
Progress in Retinal and Eye Research (2019) Vol. 73, pp. 100770-100770
Open Access | Times Cited: 375
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Jonathan Pol, Erika Vacchelli, Fernando Aranda, et al.
OncoImmunology (2015) Vol. 4, Iss. 4, pp. e1008866-e1008866
Open Access | Times Cited: 273
Clinical Development of BRAF plus MEK Inhibitor Combinations
Vivek Subbiah, Christina S. Baik, John M. Kirkwood
Trends in cancer (2020) Vol. 6, Iss. 9, pp. 797-810
Open Access | Times Cited: 255
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
Lucie Heinzerling, Thomas Eigentler, Michael Fluck, et al.
ESMO Open (2019) Vol. 4, Iss. 3, pp. e000491-e000491
Open Access | Times Cited: 185
Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities
Rebecca Kaye, Shruti Chandra, Jay Sheth, et al.
Progress in Retinal and Eye Research (2020) Vol. 79, pp. 100865-100865
Open Access | Times Cited: 180
Central serous chorioretinopathy: An evidence-based treatment guideline
Helena M. A. Feenstra, Elon H. C. van Dijk, Chui Ming Gemmy Cheung, et al.
Progress in Retinal and Eye Research (2024) Vol. 101, pp. 101236-101236
Open Access | Times Cited: 33
Clinical and Morphologic Characteristics of MEK Inhibitor–Associated Retinopathy
Jasmine H. Francis, Larissa A. Habib, David H. Abramson, et al.
Ophthalmology (2017) Vol. 124, Iss. 12, pp. 1788-1798
Open Access | Times Cited: 116
Adult-onset foveomacular vitelliform dystrophy: A fresh perspective
Itay Chowers, Liran Tiosano, Isabelle Audo, et al.
Progress in Retinal and Eye Research (2015) Vol. 47, pp. 64-85
Closed Access | Times Cited: 111
Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells
Zhen Li, Ke Jiang, Xiaofang Zhu, et al.
Cancer Letters (2015) Vol. 370, Iss. 2, pp. 332-344
Closed Access | Times Cited: 97
Ocular toxicities of MEK inhibitors and other targeted therapies
Neda Stjepanovic, Juan P. Velazquez-Martin, Philippe L. Bédard
Annals of Oncology (2016) Vol. 27, Iss. 6, pp. 998-1005
Open Access | Times Cited: 94
Systemic Treatment of Melanoma
Reinhard Dummer, Simone M. Goldinger
(2024), pp. 1-15
Closed Access | Times Cited: 10
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma
Adil Daud, Katy K. Tsai
The Oncologist (2017) Vol. 22, Iss. 7, pp. 823-833
Open Access | Times Cited: 82
MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity
K E Duncan, L Y Chang, Marena Patronas
Eye (2015) Vol. 29, Iss. 8, pp. 1003-1012
Open Access | Times Cited: 76
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management
Helen Gogas, Keith T. Flaherty, Reinhard Dummer, et al.
European Journal of Cancer (2019) Vol. 119, pp. 97-106
Open Access | Times Cited: 72
Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma
Elon H. C. van Dijk, Carla M.L. van Herpen, Marina Marinkovic, et al.
Ophthalmology (2015) Vol. 122, Iss. 9, pp. 1907-1916
Closed Access | Times Cited: 71
Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer
Marissa Weber, Michelle C. Liang, Keith T. Flaherty, et al.
JAMA Ophthalmology (2016) Vol. 134, Iss. 8, pp. 855-855
Closed Access | Times Cited: 70
MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects
U. Urner‐Bloch, Martin Urner, Nicoletta F. Jaberg-Bentele, et al.
European Journal of Cancer (2016) Vol. 65, pp. 130-138
Open Access | Times Cited: 68
Exudative retinal detachment
Radgonde Amer, Hilal Nalcı, F. Nilüfer Yalçındağ
Survey of Ophthalmology (2017) Vol. 62, Iss. 6, pp. 723-769
Closed Access | Times Cited: 65
Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression
Sarah E. Woodfield, Linna Zhang, Kathleen A. Scorsone, et al.
BMC Cancer (2016) Vol. 16, Iss. 1
Open Access | Times Cited: 61
BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
Jacek Mackiewicz, Andrzej Maćkiewicz
Współczesna Onkologia (2018) Vol. 2018, Iss. 1, pp. 68-72
Open Access | Times Cited: 60
Serous business: Delineating the broad spectrum of diseases with subretinal fluid in the macula
Elon H. C. van Dijk, Camiel J. F. Boon
Progress in Retinal and Eye Research (2021) Vol. 84, pp. 100955-100955
Open Access | Times Cited: 53
Developments in targeted therapy in melanoma
Valerie C. Amann, Egle Ramelyte, S. Thurneysen, et al.
European Journal of Surgical Oncology (2016) Vol. 43, Iss. 3, pp. 581-593
Open Access | Times Cited: 59
Page 1 - Next Page

Scroll to top